117 results on '"Caviglia, GIAN PAOLO"'
Search Results
2. FRI-392-YI Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV monoinfection, that parallels HDV replicative and cytolytic activity
3. WED-243-YI Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease
4. WED-233-YI The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease
5. SAT-031-YI Evolution of pre liver transplant cardiovascular risk factors and cardiac work-up: impact on post-transplant events
6. FRI-243 Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort
7. THU-486-YI A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events
8. FRI-251-YI Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus
9. SAT-015-YI Screening for asymptomatic coronary artery disease in liver transplant recipients: is it time to replace stress echocardiography with coronary CT angiography in selected patients?
10. FRI-314 Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
11. WED-293 Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease
12. FRI-405 Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study
13. FRI-230-YI Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and nonhepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center
14. OS-094 Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBV-DNA in the setting of a limited or even absent HBV reservoir
15. THU-517 Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: experience from two international centres
16. FRI-479-YI The role of OSM/OSMRβ axis in shaping the immunemicroenvironment favouring MASLD-related HCC immune evasion
17. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
18. Reply to: “The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis”
19. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection
20. Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
21. Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
22. De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
23. Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
24. The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
25. Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease
26. Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with non-alcoholic fatty liver disease
27. Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease
28. Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort
29. Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study
30. AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
31. Outcome of chronic delta hepatitis in Italy: A long-term cohort study
32. WED-133 - Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
33. TOP-106 - The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
34. SAT-494 - Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort
35. SAT-474 - AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
36. SAT-430 - Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study
37. THU-470 - Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease
38. THU-452 - Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insuline resistant components in subjects with non-alcoholic fatty liver disease
39. THU-435 - Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease
40. THU-425 - De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
41. THU-415 - Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
42. FRI-325 - Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
43. Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors
44. Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?
45. Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic subjects with non-alcoholic fatty liver disease
46. Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response?
47. Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease
48. Serum cytokeratin-19 fragments (CYFRA 21–1) for the prediction of overall survival in patients with hepatocellular carcinoma
49. Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
50. Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.